No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression

被引:19
作者
Evers, Jelle [1 ]
Grotenhuis, Anne J. [1 ]
Aben, Katja K. H. [1 ,2 ]
Kiemeney, Lambertus A. L. M. [1 ,3 ]
Vrieling, Alina [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Hlth Evidence, Nijmegen, Netherlands
[2] Netherlands Comprehens Canc Org, Utrecht, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Urol, Nijmegen, Netherlands
关键词
BODY-MASS; PREDICTING RECURRENCE; UROTHELIAL CARCINOMA; METFORMIN USE; RISK; OBESITY; IMPACT; SUSCEPTIBILITY; PROGNOSIS; OUTCOMES;
D O I
10.1371/journal.pone.0229384
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Non-muscle invasive bladder cancer patients are at high risk for tumour recurrence and progression, hence an intensive follow-up procedure is recommended which is costly. Identification of factors that are associated with the risk of recurrence and progression may enable personalized follow-up schedules. Obesity and diabetes mellitus may be associated with a worse prognosis, but the evidence is limited and inconsistent. Our objective was to determine the associations of BMI and diabetes mellitus with risks of recurrence and progression among non-muscle invasive bladder cancer patients. Methods A population-based cohort of patients diagnosed with non-muscle invasive bladder cancer between 1995 and 2010 was retrospectively identified from the Netherlands Cancer Registry and invited to participate in the Nijmegen Bladder Cancer Study (n = 1,433). Average weight during adult life, height, and diabetes mellitus diagnosis were self-reported by use of a questionnaire. Clinical follow-up data were retrieved from medical files. Associations were quantified using proportional hazard analyses. For all analyses, minimal adjustment sets were selected using a Directed Acyclic Graph. Results Fourteen percent of the patients indicated to be diagnosed with diabetes mellitus, and more than half was overweight (45%) or obese (9%). Compared to healthy weight, overweight and obesity were not associated with risk of recurrence (adjusted hazard ratio (HR) = 1.02; 95% confidence interval (CI): 0.86-1.22, and HR = 1.02; 95% CI: 0.76-1.38, respectively) and overall progression (HR = 1.04; 95% CI: 0.74-1.44, and HR = 1.20; 95% CI: 0.69-2.09, respectively). Also, no clear associations of diabetes mellitus with risk of recurrence (HR = 1.22; 95% CI: 0.98-1.54) and overall progression (HR = 1.16; 95% CI: 0.76-1.76) were found. Conclusion Average BMI during adult life and diabetes mellitus were not clearly associated with risk of recurrence or progression in non-muscle invasive bladder cancer. Prospective cohort studies with detailed information on BMI and diabetes mellitus before and after diagnosis are needed to confirm these findings.
引用
收藏
页数:17
相关论文
共 37 条
[21]   Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition [J].
Lamm, Donald ;
Persad, Raj ;
Brausi, Maurizio ;
Buckley, Roger ;
Witjes, J. Alfred ;
Palou, Joan ;
Boehle, Andreas ;
Kamat, Ashish M. ;
Colombel, Marc ;
Soloway, Mark .
JOURNAL OF UROLOGY, 2014, 191 (01) :20-27
[22]  
Mostofi FK., 1973, HISTOLOGICAL TYPING
[23]   Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry [J].
Ploeg, Martine ;
Aben, Katja K. ;
Hulsbergen-van de Kaa, Christina A. ;
Schoenberg, Mark P. ;
Witjes, Johannes A. ;
Kiemeney, Lambertus A. .
JOURNAL OF UROLOGY, 2010, 183 (03) :915-920
[24]   European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene [J].
Rafnar, Thorunn ;
Vermeulen, Sita H. ;
Sulem, Patrick ;
Thorleifsson, Gudmar ;
Aben, Katja K. ;
Witjes, J. Alfred ;
Grotenhuis, Anne J. ;
Verhaegh, Gerald W. ;
Hulsbergen-van de Kaa, Christina A. ;
Besenbacher, Soren ;
Gudbjartsson, Daniel ;
Stacey, Simon N. ;
Gudmundsson, Julius ;
Johannsdottir, Hrefna ;
Bjarnason, Hjordis ;
Zanon, Carlo ;
Helgadottir, Hafdis ;
Jonasson, Jon Gunnlaugur ;
Tryggvadottir, Laufey ;
Jonsson, Eirikur ;
Geirsson, Gudmundur ;
Nikulasson, Sigfus ;
Petursdottir, Vigdis ;
Bishop, D. Timothy ;
Chung-Sak, Sei ;
Choudhury, Ananya ;
Elliott, Faye ;
Barrett, Jennifer H. ;
Knowles, Margaret A. ;
de Verdier, Petra J. ;
Ryk, Charlotta ;
Lindblom, Annika ;
Rudnai, Peter ;
Gurzau, Eugene ;
Koppova, Kvetoslava ;
Vineis, Paolo ;
Polidoro, Silvia ;
Guarrera, Simonetta ;
Sacerdote, Carlotta ;
Panadero, Angeles ;
Sanz-Velez, Jose I. ;
Sanchez, Manuel ;
Valdivia, Gabriel ;
Garcia-Prats, Maria D. ;
Hengstler, Jan G. ;
Selinski, Silvia ;
Gerullis, Holger ;
Ovsiannikov, Daniel ;
Khezri, Abdolaziz ;
Aminsharifi, Alireza .
HUMAN MOLECULAR GENETICS, 2011, 20 (21) :4268-4281
[25]   Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer [J].
Rieken, Malte ;
Xylinas, Evanguelos ;
Kluth, Luis ;
Crivelli, Joseph J. ;
Chrystal, James ;
Faison, Talia ;
Lotan, Yair ;
Karakiewicz, Pierre I. ;
Fajkovic, Harun ;
Babjuk, Marek ;
Kautzky-Willer, Alexandra ;
Bachmann, Alexander ;
Scherr, Douglas S. ;
Shariat, Shahrokh F. .
BJU INTERNATIONAL, 2013, 112 (08) :1105-1112
[26]   PARTIAL RESIDUALS FOR THE PROPORTIONAL HAZARDS REGRESSION-MODEL [J].
SCHOENFELD, D .
BIOMETRIKA, 1982, 69 (01) :239-241
[27]   Diabetes and Cancer: Is Diabetes Causally Related to Cancer? [J].
Suh, Sunghwan ;
Kim, Kwang-Won .
DIABETES & METABOLISM JOURNAL, 2011, 35 (03) :193-198
[28]   Obesity and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of 15 Cohort Studies [J].
Sun, Jiang-Wei ;
Zhao, Long-Gang ;
Yang, Yang ;
Ma, Xiao ;
Wang, Ying-Ying ;
Xiang, Yong-Bing .
PLOS ONE, 2015, 10 (03)
[29]   The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease [J].
Svatek, Robert S. ;
Hollenbeck, Brent K. ;
Holmang, Sten ;
Lee, Richard ;
Kim, Simon P. ;
Stenzl, Arnulf ;
Lotan, Yair .
EUROPEAN UROLOGY, 2014, 66 (02) :253-262
[30]   Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials [J].
Sylvester, RJ ;
van der Meijden, APM ;
Oosterlinck, W ;
Witjes, JA ;
Bouffioux, C ;
Denis, L ;
Newling, DWW ;
Kurth, K .
EUROPEAN UROLOGY, 2006, 49 (03) :466-477